Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 5/20 | 0.69 |
| ▸ | AURKA | O14965 | 3/20 | 0.69 |
| ▸ | CDK1 | P06493 | 3/20 | 0.69 |
| ▸ | CDK7 | P50613 | 3/20 | 0.69 |
| ▸ | CDK9 | P50750 | 3/20 | 0.69 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.69 |
| ▸ | CDK4 | P11802 | 2/20 | 0.69 |
| ▸ | EGFR | P00533 | 3/20 | 0.60 |
| ▸ | JAK2 | O60674 | 1/20 | 0.60 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.60 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.60 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.60 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.60 |
| ▸ | ZAP70 | P43403 | 10/20 | 0.58 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.58 |
| ▸ | PRKCG | P05129 | 3/20 | 0.58 |
| ▸ | PRKCB | P05771 | 3/20 | 0.58 |
| ▸ | LCK | P06239 | 3/20 | 0.58 |
| ▸ | PRKCA | P17252 | 3/20 | 0.58 |
| ▸ | PRKCH | P24723 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14378948 | 0.86 | ZAP70 (0.70) | CDK2AURKACDK1CDK7CDK9 | |
| SCHEMBL5065681 | 0.84 | ZAP70 (0.74) | CDK2AURKACDK1CDK7CDK9 | |
| SCHEMBL14216016 | 0.83 | ZAP70 (0.72) | CDK2AURKACDK1CDK7CDK9 | |
| SCHEMBL6978008 | 0.82 | CDK2 (0.60) | CDK2AURKACDK1CDK7CDK9 | |
| SCHEMBL4159950 | 0.81 | CDK2 (1.00) | CDK2AURKACDK1CDK7CDK9 | |
| SCHEMBL6976486 | 0.81 | SYK (0.74) | CDK2AURKACDK1CDK7CDK9 | |
| SCHEMBL4156619 | 0.81 | CDK2 (1.00) | CDK2AURKACDK1CDK7CDK9 | |
| SCHEMBL2288182 | 0.81 | CDK2 (0.74) | CDK2AURKACDK1CDK7CDK9 | |
| SCHEMBL5036805 | 0.81 | CDK2 (0.65) | CDK2AURKACDK1CDK7CDK9 | |
| SCHEMBL6979315 | 0.80 | CDK2 (0.79) | CDK2AURKACDK1CDK7CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318954-A1 | Compounds | CYCLACEL LIMITED (GB) | 2008-12-25 | — | — | US | claimed |
| EP-1751146-A2 | PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY | Cyclacel Limited (GB) | 2007-02-14 | — | — | EP | claimed |
| WO-2005075468-A2 | PYRIDINYL - OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY | CYCLACEL LIMITED (GB) | 2005-08-18 | — | — | WO | claimed |
| WO-2009070328-A1 | MODULATORS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) PATHWAY FOR USE IN THE TREATMENT OR PREVENTION OF SUBSTANCE ABUSE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-06-04 | — | — | WO | disclosed |
| US-20080318954-A1 | Compounds | CYCLACEL LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| US-20080318954-A1 | Compounds | CYCLACEL LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| CN-1914199-A | Pyridyl or pyrimidyl thiazole compounds having protein kinase inhibitory activity | CYCLACEL LTD (GB) | 2007-02-14 | — | — | CN | disclosed |
| EP-1751146-A2 | PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY | Cyclacel Limited (GB) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005075468-A3 | PYRIDINYL - OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY | CYCLACEL LTD (GB) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005075468-A2 | PYRIDINYL - OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY | CYCLACEL LIMITED (GB) | 2005-08-18 | — | — | WO | disclosed |
| EP-0862560-B1 | SUBSTITUTED 2-ANILINOPYRIMIDINES USEFUL AS PROTEIN KINASE INHIBITORS | CELLTECH THERAPEUTICS LTD (GB) | 2003-04-02 | — | — | EP | disclosed |
| US-6235746-B1 | AUTOIMMUNE DISEASES; ANTIPROLIFERATIVE AGENT | CELLTECH THERAPEUTICS, LIMITED (GB) | 2001-05-22 | — | — | US | disclosed |
| US-5958935-A | Substituted 2-anilinopyrimidines useful as protein kinase inhibitors | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318954-A1 | Compounds | CBR3, NR3C2, NR5A1 | CDK2 1186/4885AURKA 2935/4885CDK1 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.